Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Heat Biologics Tightens Belt To Reach Late-2016 Inflection Points

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech striving to hold on financially until it can deliver top-line data for bladder and lung cancer immunotherapy candidates, but then it will have to content with Roche entering the bladder cancer market with its PD-L1 inhibitor.

Advertisement

Related Content

How To Catch The Next Wave Of Cancer Immunotherapy
PD-1 Progress May Shorten The Life Of Other Drugs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register